SlideShare a Scribd company logo
1 of 16
Comers To the Market
                                                            (CTM)
                                                          Walid Saafan
                                                    Marketing Information Manager
                                                            Novartis Egypt




1 Comers To the Market (CTM)-Presentation / Egypt
Topics


 Objectives
 CTM Inputs
 CTM concept
 CTM Deliverables
 CTM analysis
 Key success factors
 Conclusion
Objectives


 Monthly follow-up to New Introductions (NIs) and
 Life Cycle Management (LCM) introduced in the
 market.
 Full information about NIs/ LCM brands/ packs.
 Calculate the YTD sales impact on NIs/ LCMs on
 market(s) and corporate.
CTM update cycle
 taview report        2. Paste data into Excel tool




CTM report is ready
CTM concept


 Extract IMS Dataview report data into an Excel
 tool that re-format the data for CTM report.
 Differentiate between NI/ LCM by units sold LY. If
 Brand previous years units sold=0  NI otherwise
 LCM
 Provide all information about NIs/ LCMs brands:
 ATC3, CRP, Brand, Pack, MOL, NI/ LCM YTD
 sales, launch Month, Launch year, PSP.
 Ability to filter the report by ATC3 or CRP.
CTM deliverables – Total market
  ATC3        CRP         Brand      Pack            Mol(s)         NIs count

                                                                                LCMs count




                                            NIs YTD sales

                                                   LCMs YTD sales




                                             NI YTD sales


                                            LCM YTD sales




   Source:   CTM / IMS data Dec.06
CTM deliverables – specific ATC3
Select Class




   All results filtered on the selected class.
   New competitors information available.
   PM can follow up brands/ generics introductions
   in his market(s).
         Source:   CTM / IMS data Dec.06
CTM deliverables – specific CRP
      Select CRP




 All results filtered on the selected CRP.
 Analysis of CRPs YTD growth derived from NIs/LCM.
 Identify introduced brands by the selected CRP.

   Source:   CTM / IMS data Dec.06
CTM analysis – Leading CRPs in LCM




 Arrange CRPs in terms of YTD LCM value sales.
 Assess YTD impact of CRP new packs introduced.


   Source:   CTM / IMS data Dec.06
CTM analysis – Leading CRPs in NIs




 Arrange CRPs in terms of YTD Nis value sales.
 Assess YTD impact of CRP new brands introduced.


   Source:   CTM / IMS data Dec.06
CTM analysis – Leading ATC3 in NIs




 Arranged classes in terms of NIs to identify the attractive
 markets.
 Assess current classes that our brands compete in.

   Source:   CTM / IMS data Dec.06
CTM analysis – Leading ATC3 in LCMs




 Arranged classes in terms of LCMs to identify the
 attractive markets.
 Assess current classes that our brands compete in.

   Source:   CTM / IMS data Dec.06
Sample outputs
ading CRPs - LCM
                  Others (180),
                23,799,000 , 22%


                                                              NOVARTIS, 39,246,800
   SANOFI AVENTIS,                                                  , 35%
    2,127,700 , 2%


MERCK AG*, 3,043,000
       , 3%
  GLAXOSMITHKLINE*,
    3,471,600 , 3%
    AMOUN PHARM.CO.,
      3,896,400 , 4%
        EVA, 4,979,400 , 5%
            ABBOTT*, 5,117,000 ,
                                                           LCM breakdown per CRP
                                                       PFIZER*, 8,972,900 ,
                                                               8%    45,000,000
                   5%
                                             ALTANA*, 7,037,600 ,                                                                              MIACALCIC PLUS
                  LUNDBEC., 6,423,900 ,                                                                                  SIRDALUD 2mg 20
                                                     7%                                                                                       (08.2006), 615,300
                         6%                                          40,000,000                                          (07.2006), 542,500


                                                                                                                                  VOLTAREN AMP 75mg 6
                                                                     35,000,000
                                                                                                                                   (04.2006), 6,362,100

                                                                                                                       CATAFLAM AMP 75mg 6
                                                                     30,000,000
                                                                                                                        (04.2006) , 4,156,400
                                                                                                           ANAFRONIL 75mg 20
                                                                     25,000,000                            (02.2006), 4,306,600


                                                                     20,000,000                                                                           38.6 Mio
                                                                                                CATAFLAM 50mg 20
                                                                     15,000,000                (02.2006), 13,232,700



                                                                     10,000,000

                                                                                     FLOTAC (01.2006),
                                                                      5,000,000
                                                                                        10,031,300
                       Source:       CTM / IMS data Dec.06
                                                                            -
                                                                                                         Novartis PH
Key success factors


 Tool update can be done easily without too much
 technical knowledge (preliminary Dataview and Excel
 experience).
 Tool is applied in Novartis Egypt for almost a year and
 introduced to Novartis KSA from Oct.06.
 PMs follow up introductions in their markets on monthly
 basis or during MPH planning.
 CPO management assess their position in the market and
 follow up competitor launches on monthly basis or during
 planning or StratPlan preperation.
 BD&L can analyze the market and identify attractive
 markets in terms of number/ value of NIs & LCMs.
Conclusion


 CTM is an easy tool that give more insight about
 market dynamics.
 The tool can be adapted easily in different
 markets from small CPOs to regional level.
 Many new untapped information can be explored
 that will support marketing and senior
 management to analyze market dynamics.
 Consolidated reports can easily extracted with
 pivot reports.
Thanks


16 Comers To the Market (CTM)-Presentation / Egypt

More Related Content

What's hot

NIVEA Marketing Communication Analysis
NIVEA Marketing Communication AnalysisNIVEA Marketing Communication Analysis
NIVEA Marketing Communication Analysis
Siriwan Siriwangsanti
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Mitesh Shah
 
Case Methodolgy in Marketing Strategy: Brand Development
Case Methodolgy in Marketing Strategy: Brand DevelopmentCase Methodolgy in Marketing Strategy: Brand Development
Case Methodolgy in Marketing Strategy: Brand Development
Zac Bodner
 
Marketing: A Case Study of Cialis
Marketing: A Case Study of CialisMarketing: A Case Study of Cialis
Marketing: A Case Study of Cialis
Yee Jie NG
 

What's hot (20)

Segmentation case study-nevia
Segmentation case study-neviaSegmentation case study-nevia
Segmentation case study-nevia
 
How to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing PlanHow to Make Pharmaceutical Marketing Plan
How to Make Pharmaceutical Marketing Plan
 
L'Oréal Brandstorm 2017
L'Oréal Brandstorm 2017L'Oréal Brandstorm 2017
L'Oréal Brandstorm 2017
 
New Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical IndustryNew Product Planning in the Pharmaceutical Industry
New Product Planning in the Pharmaceutical Industry
 
Forever21
Forever21Forever21
Forever21
 
Launch plan without cannibalization the existing product mix
Launch plan without cannibalization the existing product mixLaunch plan without cannibalization the existing product mix
Launch plan without cannibalization the existing product mix
 
Kodak Case Study
Kodak Case StudyKodak Case Study
Kodak Case Study
 
Zantac
ZantacZantac
Zantac
 
NIVEA Marketing Communication Analysis
NIVEA Marketing Communication AnalysisNIVEA Marketing Communication Analysis
NIVEA Marketing Communication Analysis
 
New launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brandNew launching strategy of pharmaceutical brand
New launching strategy of pharmaceutical brand
 
Pharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process FlowPharmaceutical Business Development Process Flow
Pharmaceutical Business Development Process Flow
 
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY”
 
MarkStrat Simulation report
MarkStrat Simulation reportMarkStrat Simulation report
MarkStrat Simulation report
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
 
How Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio Medix
How Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio MedixHow Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio Medix
How Many Types of Marketing Strategies in Pharma Sector? - Ambit Bio Medix
 
Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12Generic Drugs Michael Mc Namara May 12
Generic Drugs Michael Mc Namara May 12
 
Case Methodolgy in Marketing Strategy: Brand Development
Case Methodolgy in Marketing Strategy: Brand DevelopmentCase Methodolgy in Marketing Strategy: Brand Development
Case Methodolgy in Marketing Strategy: Brand Development
 
Marketing: A Case Study of Cialis
Marketing: A Case Study of CialisMarketing: A Case Study of Cialis
Marketing: A Case Study of Cialis
 
Market Analysis of Gillette India Limited - 2009
Market Analysis of Gillette India Limited - 2009Market Analysis of Gillette India Limited - 2009
Market Analysis of Gillette India Limited - 2009
 
Gap Inc. - Case Analysis (Strategic Audit)
Gap Inc. - Case Analysis (Strategic Audit)Gap Inc. - Case Analysis (Strategic Audit)
Gap Inc. - Case Analysis (Strategic Audit)
 

Similar to PHARMA-How to Identify NI & LCM from IMS data

Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12
pmcurran1
 
merck 4Q06 Other Financial Disclosures
merck  	4Q06 Other Financial Disclosuresmerck  	4Q06 Other Financial Disclosures
merck 4Q06 Other Financial Disclosures
finance11
 
energy future holindings _032905
energy future holindings _032905energy future holindings _032905
energy future holindings _032905
finance29
 
energy future holindings 032905
energy future holindings 032905energy future holindings 032905
energy future holindings 032905
finance29
 
Presentacin indijun2009
Presentacin indijun2009Presentacin indijun2009
Presentacin indijun2009
redasomi
 
Stock quotes 11112014
Stock quotes 11112014Stock quotes 11112014
Stock quotes 11112014
srichardequip
 
Stock quotes 11122014
Stock quotes 11122014Stock quotes 11122014
Stock quotes 11122014
srichardequip
 

Similar to PHARMA-How to Identify NI & LCM from IMS data (20)

PHARMA Market Elements of Growth (MEGR)
PHARMA Market Elements of Growth (MEGR)PHARMA Market Elements of Growth (MEGR)
PHARMA Market Elements of Growth (MEGR)
 
EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010EGYPT Osteoporosis market analysis 2010
EGYPT Osteoporosis market analysis 2010
 
Walid saafan pharma_experience
Walid saafan pharma_experienceWalid saafan pharma_experience
Walid saafan pharma_experience
 
Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12Btf exhibitors presentation, atlantis, 5 25-12
Btf exhibitors presentation, atlantis, 5 25-12
 
Process flow of sales forecasting and supply chain
Process flow of  sales forecasting and supply chainProcess flow of  sales forecasting and supply chain
Process flow of sales forecasting and supply chain
 
merck 4Q06 Other Financial Disclosures
merck  	4Q06 Other Financial Disclosuresmerck  	4Q06 Other Financial Disclosures
merck 4Q06 Other Financial Disclosures
 
energy future holindings _032905
energy future holindings _032905energy future holindings _032905
energy future holindings _032905
 
energy future holindings 032905
energy future holindings 032905energy future holindings 032905
energy future holindings 032905
 
Iochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results PresentationIochpe-Maxion - 1Q09 Results Presentation
Iochpe-Maxion - 1Q09 Results Presentation
 
Team Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation UpdatedTeam Professionals VMobile Presentation Updated
Team Professionals VMobile Presentation Updated
 
Iochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 PresentationIochpe-Maxion - 3Q09 Presentation
Iochpe-Maxion - 3Q09 Presentation
 
Presentacin indijun2009
Presentacin indijun2009Presentacin indijun2009
Presentacin indijun2009
 
Biopower in australia
Biopower in australiaBiopower in australia
Biopower in australia
 
Q1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation FinalQ1 2009 Analyst Presentation Final
Q1 2009 Analyst Presentation Final
 
Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14Asml 20070914 2007 09 14 Db London Sept 14
Asml 20070914 2007 09 14 Db London Sept 14
 
Stock quotes 11112014
Stock quotes 11112014Stock quotes 11112014
Stock quotes 11112014
 
Stock quotes 11122014
Stock quotes 11122014Stock quotes 11122014
Stock quotes 11122014
 
European Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery DevicesEuropean Markets for Cardiac Surgery Devices
European Markets for Cardiac Surgery Devices
 
Presentation2
Presentation2Presentation2
Presentation2
 
Presentation2
Presentation2Presentation2
Presentation2
 

More from Walid Saafan

More from Walid Saafan (20)

Mclaren the banking sector v2
Mclaren the banking sector v2Mclaren the banking sector v2
Mclaren the banking sector v2
 
EGP flotation impact on some banks
EGP flotation impact on some banksEGP flotation impact on some banks
EGP flotation impact on some banks
 
ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18ABK Egypt financial statements H1 18
ABK Egypt financial statements H1 18
 
ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18ABK Egypt financials' summary H1-18
ABK Egypt financials' summary H1-18
 
NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18NBK Egypt financial statement H1-18
NBK Egypt financial statement H1-18
 
NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18NBK-Egypt financials summary H1-18
NBK-Egypt financials summary H1-18
 
Facebook effect on SMEs in Egypt
Facebook effect on SMEs in EgyptFacebook effect on SMEs in Egypt
Facebook effect on SMEs in Egypt
 
Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016Infographic: Fastest growing Egyptian banks in t.assets 03.2016
Infographic: Fastest growing Egyptian banks in t.assets 03.2016
 
Branch location for selected banks
Branch location for selected banksBranch location for selected banks
Branch location for selected banks
 
Entrepreneurship as disease
Entrepreneurship as diseaseEntrepreneurship as disease
Entrepreneurship as disease
 
Corporate values' Evaluation
Corporate values' EvaluationCorporate values' Evaluation
Corporate values' Evaluation
 
Strategic Alliance
Strategic AllianceStrategic Alliance
Strategic Alliance
 
'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book review'Blue Ocean Strategy' book review
'Blue Ocean Strategy' book review
 
Egypt privatization program
Egypt privatization programEgypt privatization program
Egypt privatization program
 
Strategic Alliance failure
Strategic Alliance failureStrategic Alliance failure
Strategic Alliance failure
 
Basel II – Integrated Risk Capital
Basel II – Integrated Risk CapitalBasel II – Integrated Risk Capital
Basel II – Integrated Risk Capital
 
Options trading markets
Options trading marketsOptions trading markets
Options trading markets
 
How are banking ratios compiled
How are banking ratios compiledHow are banking ratios compiled
How are banking ratios compiled
 
Corporate culture a source for competitive advantage
Corporate culture a source for competitive advantageCorporate culture a source for competitive advantage
Corporate culture a source for competitive advantage
 
What is STRATEGY?
What is STRATEGY?What is STRATEGY?
What is STRATEGY?
 

Recently uploaded

CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
ocean4396
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 

Recently uploaded (20)

TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)Cervical screening – taking care of your health flipchart (Vietnamese)
Cervical screening – taking care of your health flipchart (Vietnamese)
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
 
HyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdfHyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdf
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
hypo and hyper thyroidism final lecture.pptx
hypo and hyper thyroidism  final lecture.pptxhypo and hyper thyroidism  final lecture.pptx
hypo and hyper thyroidism final lecture.pptx
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
CAS 110-63-4 BDO Liquid 1,4-Butanediol 1 4 BDO Warehouse Supply For Excellent...
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 
Evidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapyEvidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapy
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Denture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of actionDenture base resins materials and its mechanism of action
Denture base resins materials and its mechanism of action
 
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. MacklinScleroderma: Treatment Options and a Look to the Future - Dr. Macklin
Scleroderma: Treatment Options and a Look to the Future - Dr. Macklin
 

PHARMA-How to Identify NI & LCM from IMS data

  • 1. Comers To the Market (CTM) Walid Saafan Marketing Information Manager Novartis Egypt 1 Comers To the Market (CTM)-Presentation / Egypt
  • 2. Topics Objectives CTM Inputs CTM concept CTM Deliverables CTM analysis Key success factors Conclusion
  • 3. Objectives Monthly follow-up to New Introductions (NIs) and Life Cycle Management (LCM) introduced in the market. Full information about NIs/ LCM brands/ packs. Calculate the YTD sales impact on NIs/ LCMs on market(s) and corporate.
  • 4. CTM update cycle taview report 2. Paste data into Excel tool CTM report is ready
  • 5. CTM concept Extract IMS Dataview report data into an Excel tool that re-format the data for CTM report. Differentiate between NI/ LCM by units sold LY. If Brand previous years units sold=0  NI otherwise LCM Provide all information about NIs/ LCMs brands: ATC3, CRP, Brand, Pack, MOL, NI/ LCM YTD sales, launch Month, Launch year, PSP. Ability to filter the report by ATC3 or CRP.
  • 6. CTM deliverables – Total market ATC3 CRP Brand Pack Mol(s) NIs count LCMs count NIs YTD sales LCMs YTD sales NI YTD sales LCM YTD sales Source: CTM / IMS data Dec.06
  • 7. CTM deliverables – specific ATC3 Select Class All results filtered on the selected class. New competitors information available. PM can follow up brands/ generics introductions in his market(s). Source: CTM / IMS data Dec.06
  • 8. CTM deliverables – specific CRP Select CRP All results filtered on the selected CRP. Analysis of CRPs YTD growth derived from NIs/LCM. Identify introduced brands by the selected CRP. Source: CTM / IMS data Dec.06
  • 9. CTM analysis – Leading CRPs in LCM Arrange CRPs in terms of YTD LCM value sales. Assess YTD impact of CRP new packs introduced. Source: CTM / IMS data Dec.06
  • 10. CTM analysis – Leading CRPs in NIs Arrange CRPs in terms of YTD Nis value sales. Assess YTD impact of CRP new brands introduced. Source: CTM / IMS data Dec.06
  • 11. CTM analysis – Leading ATC3 in NIs Arranged classes in terms of NIs to identify the attractive markets. Assess current classes that our brands compete in. Source: CTM / IMS data Dec.06
  • 12. CTM analysis – Leading ATC3 in LCMs Arranged classes in terms of LCMs to identify the attractive markets. Assess current classes that our brands compete in. Source: CTM / IMS data Dec.06
  • 13. Sample outputs ading CRPs - LCM Others (180), 23,799,000 , 22% NOVARTIS, 39,246,800 SANOFI AVENTIS, , 35% 2,127,700 , 2% MERCK AG*, 3,043,000 , 3% GLAXOSMITHKLINE*, 3,471,600 , 3% AMOUN PHARM.CO., 3,896,400 , 4% EVA, 4,979,400 , 5% ABBOTT*, 5,117,000 , LCM breakdown per CRP PFIZER*, 8,972,900 , 8% 45,000,000 5% ALTANA*, 7,037,600 , MIACALCIC PLUS LUNDBEC., 6,423,900 , SIRDALUD 2mg 20 7% (08.2006), 615,300 6% 40,000,000 (07.2006), 542,500 VOLTAREN AMP 75mg 6 35,000,000 (04.2006), 6,362,100 CATAFLAM AMP 75mg 6 30,000,000 (04.2006) , 4,156,400 ANAFRONIL 75mg 20 25,000,000 (02.2006), 4,306,600 20,000,000 38.6 Mio CATAFLAM 50mg 20 15,000,000 (02.2006), 13,232,700 10,000,000 FLOTAC (01.2006), 5,000,000 10,031,300 Source: CTM / IMS data Dec.06 - Novartis PH
  • 14. Key success factors Tool update can be done easily without too much technical knowledge (preliminary Dataview and Excel experience). Tool is applied in Novartis Egypt for almost a year and introduced to Novartis KSA from Oct.06. PMs follow up introductions in their markets on monthly basis or during MPH planning. CPO management assess their position in the market and follow up competitor launches on monthly basis or during planning or StratPlan preperation. BD&L can analyze the market and identify attractive markets in terms of number/ value of NIs & LCMs.
  • 15. Conclusion CTM is an easy tool that give more insight about market dynamics. The tool can be adapted easily in different markets from small CPOs to regional level. Many new untapped information can be explored that will support marketing and senior management to analyze market dynamics. Consolidated reports can easily extracted with pivot reports.
  • 16. Thanks 16 Comers To the Market (CTM)-Presentation / Egypt

Editor's Notes

  1. FF input is validated by IMS MAT units sales per territory and zone. IMS units is fine tuned by two factors: TAR DRs visited against the total market universe. # of boxes sold without RXs.